Cargando…

Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis

OBJECTIVES: To investigate the safety of live attenuated varicella zoster vaccination when administered to immunosuppressed individuals. DESIGN: Prospective observational cohort study. SETTING: The study used anonymised data from the Clinical Practice Research Datalink (CPRD), comprising a represent...

Descripción completa

Detalles Bibliográficos
Autores principales: Grint, Daniel J, McDonald, Helen I, Walker, Jemma L, Amirthalingam, Gayatri, Andrews, Nick, Thomas, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045073/
https://www.ncbi.nlm.nih.gov/pubmed/32001495
http://dx.doi.org/10.1136/bmjopen-2019-034886
_version_ 1783501704477540352
author Grint, Daniel J
McDonald, Helen I
Walker, Jemma L
Amirthalingam, Gayatri
Andrews, Nick
Thomas, Sara
author_facet Grint, Daniel J
McDonald, Helen I
Walker, Jemma L
Amirthalingam, Gayatri
Andrews, Nick
Thomas, Sara
author_sort Grint, Daniel J
collection PubMed
description OBJECTIVES: To investigate the safety of live attenuated varicella zoster vaccination when administered to immunosuppressed individuals. DESIGN: Prospective observational cohort study. SETTING: The study used anonymised data from the Clinical Practice Research Datalink (CPRD), comprising a representative sample of routinely collected primary care data in England between 2013 and 2017 and and linked Hospital Episode Statistics data. PARTICIPANTS: 168 767 individuals age-eligible for varicella zoster vaccination registered at a general practice in England contributing data to CPRD. MAIN OUTCOME MEASURES: Electronic health records indicating immunosuppression, zoster vaccination, diagnoses of specific varicella-zoster virus (VZV)-related disease and non-specific rash/encephalitis compatible with VZV-related disease. RESULTS: Between 1 September 2013 and 31 August 2017, a period of immunosuppression was identified for 9093/168 767 (5.4%; 95% CI: 5.3%–5.5%) individuals age-eligible for zoster vaccination. The overall rate of vaccination while immunosuppressed was 1742/5251 (33.2 per 100 adjusted person years at risk; 95% CI: 31.9%–34.5%). Follow-up of the 1742 individuals who were inadvertently vaccinated while immunosuppressed identified only two cases of VZV-related disease within 8 weeks of vaccination (0.1%; 95% CI: 0.01%–0.4%), both primary care diagnoses of ‘shingles’, neither with a related hospital admission. CONCLUSIONS: Despite evidence of inadvertent vaccination of immunosuppressed individuals with live zoster vaccination, there is a lack of evidence of severe consequences including hospitalisation. This should reassure primary care staff and encourage vaccination of mildly immunosuppressed individuals who do not meet current thresholds for contraindication. These findings support a review of the extent to which live zoster vaccination is contraindicated among the immunosuppressed.
format Online
Article
Text
id pubmed-7045073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70450732020-03-09 Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis Grint, Daniel J McDonald, Helen I Walker, Jemma L Amirthalingam, Gayatri Andrews, Nick Thomas, Sara BMJ Open Public Health OBJECTIVES: To investigate the safety of live attenuated varicella zoster vaccination when administered to immunosuppressed individuals. DESIGN: Prospective observational cohort study. SETTING: The study used anonymised data from the Clinical Practice Research Datalink (CPRD), comprising a representative sample of routinely collected primary care data in England between 2013 and 2017 and and linked Hospital Episode Statistics data. PARTICIPANTS: 168 767 individuals age-eligible for varicella zoster vaccination registered at a general practice in England contributing data to CPRD. MAIN OUTCOME MEASURES: Electronic health records indicating immunosuppression, zoster vaccination, diagnoses of specific varicella-zoster virus (VZV)-related disease and non-specific rash/encephalitis compatible with VZV-related disease. RESULTS: Between 1 September 2013 and 31 August 2017, a period of immunosuppression was identified for 9093/168 767 (5.4%; 95% CI: 5.3%–5.5%) individuals age-eligible for zoster vaccination. The overall rate of vaccination while immunosuppressed was 1742/5251 (33.2 per 100 adjusted person years at risk; 95% CI: 31.9%–34.5%). Follow-up of the 1742 individuals who were inadvertently vaccinated while immunosuppressed identified only two cases of VZV-related disease within 8 weeks of vaccination (0.1%; 95% CI: 0.01%–0.4%), both primary care diagnoses of ‘shingles’, neither with a related hospital admission. CONCLUSIONS: Despite evidence of inadvertent vaccination of immunosuppressed individuals with live zoster vaccination, there is a lack of evidence of severe consequences including hospitalisation. This should reassure primary care staff and encourage vaccination of mildly immunosuppressed individuals who do not meet current thresholds for contraindication. These findings support a review of the extent to which live zoster vaccination is contraindicated among the immunosuppressed. BMJ Publishing Group 2020-01-29 /pmc/articles/PMC7045073/ /pubmed/32001495 http://dx.doi.org/10.1136/bmjopen-2019-034886 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Public Health
Grint, Daniel J
McDonald, Helen I
Walker, Jemma L
Amirthalingam, Gayatri
Andrews, Nick
Thomas, Sara
Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis
title Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis
title_full Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis
title_fullStr Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis
title_full_unstemmed Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis
title_short Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis
title_sort safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a uk-based observational cohort analysis
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045073/
https://www.ncbi.nlm.nih.gov/pubmed/32001495
http://dx.doi.org/10.1136/bmjopen-2019-034886
work_keys_str_mv AT grintdanielj safetyofinadvertentadministrationoflivezostervaccinetoimmunosuppressedindividualsinaukbasedobservationalcohortanalysis
AT mcdonaldheleni safetyofinadvertentadministrationoflivezostervaccinetoimmunosuppressedindividualsinaukbasedobservationalcohortanalysis
AT walkerjemmal safetyofinadvertentadministrationoflivezostervaccinetoimmunosuppressedindividualsinaukbasedobservationalcohortanalysis
AT amirthalingamgayatri safetyofinadvertentadministrationoflivezostervaccinetoimmunosuppressedindividualsinaukbasedobservationalcohortanalysis
AT andrewsnick safetyofinadvertentadministrationoflivezostervaccinetoimmunosuppressedindividualsinaukbasedobservationalcohortanalysis
AT thomassara safetyofinadvertentadministrationoflivezostervaccinetoimmunosuppressedindividualsinaukbasedobservationalcohortanalysis